For this reason, only a preliminary tumour study was carried out in mice, but the evidence we have suggests that C-terminal antibodies targeting all VEGF-Axxxa isoforms, when they can be generated, are at least as effective as receptor binding domain antibodies such as ranibizumab or bevacizumab at inhibiting VEGF-A165. The gene discussed is VEGFA; the disease is neoplasm.